



Supplemental Material to:


**Elodie Lainey, Alice Wolfromm, Abdul Qader Sukkurwala,
Jean-Baptiste Micol, Pierre Fenaux, Lorenzo Galluzzi,
Oliver Kepp, and Guido Kroemer**

**EGFR inhibitors exacerbate differentiation and cell cycle
arrest induced by retinoic acid and vitamin D3 in acute
myeloid leukemia cells**

Cell Cycle 2013; 12(18)

<http://dx.doi.org/10.4161/cc.26016>

<http://www.landesbioscience.com/journals/cc/article/26016>



Suppl. Figure 1

Supplementary Figure 1. Differentiation-inducing effects of EGFR inhibitors on MOLM-13 cells. Human acute myeloid leukemia MOLM-13 cells were treated with 10 μ M erlotinib (ERLO), 10 μ M gefitinib (GEFI) or an equal volume of DMSO, alone or in combination with 100 nM all-*trans* retinoic acid (ATRA) or 50 nM 1 α ,25-hydroxycholecalciferol (VD), for 72h, then processed for the cytofluorometric assessment of CD11b expression upon immunostaining with a CD11b-specific antibody. Quantitative data on the percentage of CD11b-expressing cells are reported (means \pm SEM; n = 3). ** p <0.01, *** p <0.001 (ANOVA plus Dunnett's test), as compared to DMSO-treated cells; ### p <0.001 (ANOVA plus Bonferroni's post-hoc test), as compared to ATRA-treated cells; +++ p <0.001 (ANOVA plus Bonferroni's post-hoc test), as compared to VD-treated cells.

Supplementary Table 1. Genetic features of AML patients included in this study.

Patient N ^o	Sex	Age (y)	Diagnosis	Relapse	Karyotype	Mutations
1	M	70	sAML	No	Complex	<i>WT1</i> _o
2	F	80	AML1	No	46, XX	<i>NPM1</i> _m / <i>IDH1</i> _m
3	F	27	AML2	No	46, XX	<i>KMT2A</i> _d
4	F	39	AML1	No	46, XX	<i>CEBPA</i> _m
5	M	82	sAML	No	45, XY, -7	na
6	F	76	AML6	Yes	46, XX	<i>NPM1</i> _m
7	M	23	AML1	No	Complex	<i>WT1</i> _o
8	F	33	AML2	Yes	46, XX, t(8;21)	<i>FLT3</i> _{itd}
9	F	53	AML5	No	46, XX	<i>NPM1</i> _m
10	F	57	sAML	Yes	46, XX	na
11	F	34	AML1	Yes	na	na
12	M	23	sAML	No	Hyperdiploid	WT
13	M	24	sAML	No	Hyperdiploid	na
14	M	54	AML4	No	46, XY	<i>NPM1</i> _m / <i>FLT3</i> _{itd}
15	F	62	AML1	Yes	45, XX, -7	<i>WT1</i> _o
16	F	67	sAML	No	46, XX	<i>NPM1</i> _m / <i>FLT3</i> _{itd}
17	F	75	AML0	No	45, XX, del17p	WT
18	M	41	AML6	No	46, XX, t(3;5)	<i>WT1</i> _o
19	M	84	sAML	No	46, XY, del11q	na
20	M	59	AML1	No	46, XY, del17p, +8	<i>NPM1</i> _m
21	M	55	AML4	No	45, XY, -7	<i>WT1</i> _o
22	M	28	AML2	No	46, XY	<i>FLT3</i> _{itd}
23	M	56	AML5	No	46, XY, t(9;11)	WT
24	F	63	AML4	No	46, XY	na

Abbreviations: AML, acute myeloid leukemia; dup, duplication; itd, internal tandem duplication; m, mutation; na, not available; o, overexpression; s, secondary; WT, wild type.